{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:06:34Z","timestamp":1785859594205,"version":"3.56.0"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K07238"],"award-info":[{"award-number":["18K07238"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07128"],"award-info":[{"award-number":["21K07128"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H02831"],"award-info":[{"award-number":["22H02831"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in-Aid for Scientific Research","award":["18K07238"],"award-info":[{"award-number":["18K07238"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["21K07128"],"award-info":[{"award-number":["21K07128"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["22H02831"],"award-info":[{"award-number":["22H02831"]}]},{"name":"Shinnihon Foundation of Advanced Medical Treatment Research","award":["18K07238"],"award-info":[{"award-number":["18K07238"]}]},{"name":"Shinnihon Foundation of Advanced Medical Treatment Research","award":["21K07128"],"award-info":[{"award-number":["21K07128"]}]},{"name":"Shinnihon Foundation of Advanced Medical Treatment Research","award":["22H02831"],"award-info":[{"award-number":["22H02831"]}]},{"name":"Takeda Science Foundation","award":["18K07238"],"award-info":[{"award-number":["18K07238"]}]},{"name":"Takeda Science Foundation","award":["21K07128"],"award-info":[{"award-number":["21K07128"]}]},{"name":"Takeda Science Foundation","award":["22H02831"],"award-info":[{"award-number":["22H02831"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>N-myc downstream-regulated gene 2 (NDRG2), which is a tumour suppressor, is frequently lost in many types of tumours, including adult T-cell leukaemia\/lymphoma (ATL). The downregulation of NDRG2 expression is involved in tumour progression through the aberrant phosphorylation of several important signalling molecules. We observed that the downregulation of NDRG2 induced the translocation of protein arginine methyltransferase 5 (PRMT5) from the nucleus to the cytoplasm via the increased phosphorylation of PRMT5 at Serine 335. In NDRG2low ATL, cytoplasmic PRMT5 enhanced HSP90A chaperone activity via arginine methylation, leading to tumour progression and the maintenance of oncogenic client proteins. Therefore, we examined whether the inhibition of PRMT5 activity is a drug target in NDRG2low tumours. The knockdown of PRMT5 and binding partner methylsome protein 50 (MEP50) expression significantly demonstrated the suppression of cell proliferation via the degradation of AKT and NEMO in NDRG2low ATL cells, whereas NDRG2-expressing cells did not impair the stability of client proteins. We suggest that the relationship between PRMT5\/MEP50 and the downregulation of NDRG2 may exhibit a novel vulnerability and a therapeutic target. Treatment with the PRMT5-specific inhibitors CMP5 and HLCL61 was more sensitive in NDRG2low cancer cells than in NDRG2-expressing cells via the inhibition of HSP90 arginine methylation, along with the degradation of client proteins. Thus, interference with PRMT5 activity has become a feasible and effective strategy for promoting cancer vulnerability in NDRG2low ATL.<\/jats:p>","DOI":"10.3390\/ijms25052842","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:07:53Z","timestamp":1709273273000},"page":"2842","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhibition of PRMT5\/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia\/Lymphoma"],"prefix":"10.3390","volume":"25","author":[{"given":"Tomonaga","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki 889-1692, Japan"},{"name":"Department of Microbiology, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Suekane","sequence":"additional","affiliation":[{"name":"Trauma and Acute Critical Care Center, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakahata","sequence":"additional","affiliation":[{"name":"Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki 889-1692, Japan"},{"name":"Division of HTLV-1\/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima 890-8544, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Iha","sequence":"additional","affiliation":[{"name":"Division of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu 879-5503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki 889-1692, Japan"},{"name":"Project for Advanced Medical Research and Development, Project Research Division, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Iwanaga, M. (2020). Epidemiology of HTLV-1 Infection and ATL in Japan: An Update. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01124"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1498","DOI":"10.1093\/cid\/ciaa1401","article-title":"Pulmonary Disease Is Associated With Human T-Cell Leukemia Virus Type 1c Infection: A Cross-sectional Survey in Remote Aboriginal Communities","volume":"73","author":"Einsiedel","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.bbadis.2019.07.001","article-title":"The regulation of NDRG2 expression during ATLL development after HTLV-1 infection","volume":"1865","author":"Ichikawa","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1158\/0008-5472.CAN-16-2114","article-title":"Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential","volume":"77","author":"Tamura","year":"2017","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lee, K.W., Lim, S., and Kim, K.D. (2022). The Function of N-Myc Downstream-Regulated Gene 2 (NDRG2) as a Negative Regulator in Tumor Cell Metastasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169365"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1038\/ncomms4393","article-title":"Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers","volume":"5","author":"Nakahata","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.1038\/srep12841","article-title":"Loss of NDRG2 enhanced activation of the NF-\u03baB pathway by PTEN and NIK phosphorylation for ATL and other cancer development","volume":"5","author":"Ichikawa","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ichikawa, T., Shanab, O., Nakahata, S., Shimosaki, S., Manachai, N., Ono, M., Iha, H., Shimoda, K., and Morishita, K. (2019). Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells. Biochim. Biophys. Acta (BBA)-Mol. Cell Res., 1867.","DOI":"10.1016\/j.bbamcr.2019.118615"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hartley, A.-V., Wang, B., Jiang, G., Wei, H., Sun, M., Prabhu, L., Martin, M., Safa, A., Sun, S., and Liu, Y. (2020). Regulation of a PRMT5\/NF-\u03baB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103684"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"40590","DOI":"10.1038\/srep40590","article-title":"Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells","volume":"7","author":"Sipos","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1172\/JCI81749","article-title":"Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis","volume":"125","author":"Liu","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M110.148486","article-title":"RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity","volume":"286","author":"Guderian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/embor.2008.45","article-title":"The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5","volume":"9","author":"Lacroix","year":"2008","journal-title":"EMBO Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20538","DOI":"10.1073\/pnas.1106946108","article-title":"Structural insights into protein arginine symmetric dimethylation by PRMT5","volume":"108","author":"Sun","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2016.205","article-title":"A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression","volume":"36","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.humpath.2014.02.013","article-title":"Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition","volume":"45","author":"Ibrahim","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-21-0103","article-title":"Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation","volume":"21","author":"Owens","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-Associated PRMT5 Methylates Histone H3 Arginine 8 and Negatively Regulates Expression of ST7 and NM23 Tumor Suppressor Genes","volume":"24","author":"Pal","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Kuplast","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1021\/acsmedchemlett.5b00380","article-title":"Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666","volume":"7","author":"Duncan","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/jcmm.14036","article-title":"Targeting PRMT5\/Akt signalling axis prevents human lung cancer cell growth","volume":"23","author":"Zhang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: Gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18632\/oncotarget.6228","article-title":"Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer","volume":"7","author":"Hu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10495-016-1244-3","article-title":"Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers","volume":"21","author":"Hu","year":"2016","journal-title":"Apoptosis"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kim, G., Lim, S., and Kim, K.D. (2021). N-myc Downstream-Regulated Gene 2 (NDRG2) Function as a Positive Regulator of Apoptosis: A New Insight into NDRG2 as a Tumor Suppressor. Cells, 10.","DOI":"10.3390\/cells10102649"},{"key":"ref_33","first-page":"241","article-title":"Development of synthetic lethality in cancer: Molecular and cellular classification. Signal Transduct","volume":"5","author":"Li","year":"2020","journal-title":"Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","article-title":"Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation","volume":"13","author":"Topatana","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Martin","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ernzen, K., Melvin, C., Yu, L., Phelps, C., Niewiesk, S., Green, P.L., and Panfil, A.R. (2023). The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1101544"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Panfil, A.R., Al-Saleem, J., Howard, C.M., Mates, J.M., Kwiek, J.J., Baiocchi, R.A., and Green, P.L. (2015). PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival. Viruses, 8.","DOI":"10.3390\/v8010007"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1021\/acs.jmedchem.2c01000","article-title":"Discovery and Biological Characterization of PRMT5:MEP50 Protein\u2013Protein Interaction Inhibitors","volume":"65","author":"Asberry","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15300","DOI":"10.1021\/acs.jmedchem.2c01273","article-title":"Development of Macrocyclic PRMT5\u2013Adaptor Protein Interaction Inhibitors","volume":"65","author":"Krzyzanowski","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1021\/acs.jmedchem.1c00507","article-title":"Discovery of a First-in-Class Inhibitor of the PRMT5\u2013Substrate Adaptor Interaction","volume":"64","author":"McKinney","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/294770a0","article-title":"Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells","volume":"294","author":"Miyoshi","year":"1981","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V91.11.4265","article-title":"Interleukin-15 (IL-15) Can Replace the IL-2 Signal in IL-2\u2013Dependent Adult T-Cell Leukemia (ATL) Cell Lines: Expression of IL-15 Receptor \u03b1 on ATL Cells","volume":"91","author":"Yamada","year":"1998","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.189.7.1063","article-title":"Fas Gene Mutation in the Progression of Adult T Cell Leukemia","volume":"189","author":"Maeda","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1128\/jvi.65.12.6892-6899.1991","article-title":"Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: Evidence for a pretranslational component of regulation","volume":"65","author":"Arima","year":"1991","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1084\/jem.162.6.2169","article-title":"Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement","volume":"162","author":"Maeda","year":"1985","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cct.2008.05.009","article-title":"Nonlinear model-based estimates of IC50 for studies involving continuous therapeutic dose\u2013response data","volume":"29","author":"Lyles","year":"2008","journal-title":"Contemp. Clin. Trials"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2842\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:21Z","timestamp":1760105241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052842"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052842","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}